# Independent scientific contribution review of the integrated manuscript

Reviewed 11 October 2026. Actual reviewed artifact: `/Users/swethasunilkumar/Documents/Codex/2026-10-08/go/outputs/Cell_Genomics_V8_Manuscript_Review_2026-10-11/Integrated_Sleep_Atlas_Manuscript_Review_Draft.docx`. Paragraph identifiers below refer to top-level Word body paragraphs, including headings/empty paragraphs, extracted from the actual saved document. The builder `/Users/swethasunilkumar/Documents/Codex/2026-10-08/go/work/build_integrated_manuscript_v8.py` was also read for consistency. No document/builder edit, estimator fit, download or research expansion was performed. This is independent automated scientific review, not human peer review or institutional approval.

## Verdict

**A coherent, scientifically qualified resource-manuscript review draft; major contribution and release questions remain before submission.** The draft integrates historical correlation estimates, source-aware dictionaries, a bounded comparison with existing resources, a real source-direction finding, a safe interpretation candidate and one actually completed new exploratory estimate. It appropriately declines to convert numerical reproduction into source validity or an outcome-reused extension into independent replication. No unsupported gene, cell type, mechanism, causal direction or field-level first-discovery claim was identified in the actual Results/Discussion/captions.

The paper's most defensible contribution is improving how a defined atlas's existing evidence can be interpreted and reused, demonstrated by specific scientific decisions. That can be a resource contribution without inventing a novel inference method. Whether it is substantial enough for Cell Genomics remains an investigator/editorial judgment; the current manuscript does not establish comparative user benefit, broad resource superiority or acceptance. The draft correctly says so. Its remaining weakness is that the central value proposition is still more potential than demonstrated, and much of Results describes recovery/reproduction logistics rather than the scientific consequences of using the atlas.

## Evidence supporting the scientific coherence

1. The 396, 1,200 and 217-candidate families remain distinct. Historical positives are explicitly historical classifications, and current source-held records are not counted as cleared biological associations. Figure 1 preserves all record positions and distinguishes 36 direction holds, 63 additional QC failures and 297 displayed estimates irrespective of BH significance.
2. The bowel-source assessment is a substantive correctness finding: all 22 eligible published controls conflict with the assumed convention. The manuscript avoids extrapolating this to every variant, author fault, representative resource error prevalence or an authoritative global correction. Holding signed interpretation is consistent with the independent discrepancy review and actual release review.
3. The source-extension estimate is an actual new project result (rg=0.3991207522, SE=0.0506959384, nominal interval 0.2997585388–0.4984829656), with independent within-fit arithmetic and preserved limits. The draft distinguishes historical outcome reuse, selection, source ascertainment and LD/uncertainty assumptions. The three-point figure is explicitly not a contrast/equivalence test.
4. The four-snapshot benchmark is presented as bounded comparability, not a literature-wide novelty search. Zero certified exact matches is appropriately attributed to lack of established exact identity, not proof of unique associations.
5. Human pilot preparation is not reported as human evidence. No local/molecular result is invented. Code availability is separated from source-data/public-resource clearance.

These are scientific strengths, not merely software receipts. The new empirical estimate provides evidence of positive common-variant sharing under its assumptions; the source-direction finding changes interpretation of existing results. Query examples demonstrate implemented evidence retrieval, while empirical benefit to researchers remains unmeasured.

## Exact wording corrections

| Location and current wording | Scientific issue | Recommended correction |
|---|---|---|
| P32, “The MVP supplied SE was missing.” | The independent source review establishes missing supplied SE in the bounded inspected sample; a literal SE field exists in the original body. Unless a whole-source missingness result is separately documented, this sentence overstates the inspection scope. | “Supplied MVP SE values were unavailable in the bounded inspected sample; the preserved pipeline used CI-derived uncertainty.” Cite the bounded diagnostic and retain the explicit assumption. |
| P32, “...used constant effective sample size and retained its source-specific HapMap3 fallback.” | The pronoun attaches the missing-INFO fallback to MVP. The source contract describes FinnGen's absent INFO/HM3 fallback and MVP's supplied r2>0.9 filtering plus HM3 restriction. | “Both inputs used constant effective N. FinnGen used the documented HapMap3 route because endpoint INFO was unavailable; MVP retained its supplied r2 filtering and HapMap3 restriction.” Do not imply newly verified per-variant N/INFO. |
| P63, “Participant reuse induces dependence among discovery, validation and source-extension estimates.” | Reuse of identical GWAS summaries is established; individual cross-enrollment between differently named cohorts remains unverified. The current wording can suggest actual cross-cohort participant intersections were established. | “Reuse of the same GWAS summaries induces dependence among relevant discovery, external-outcome and source-extension estimates; individual cross-cohort enrollment remains unverified.” |
| P59, “...reconstructs SE from the logged interval width divided by twice 1.959963984540054.” | “Logged interval width” is ambiguous: log(upper−lower) would be wrong. The pipeline uses the difference of logged bounds. | Give the formula explicitly: `SE_logOR=[log(ci_upper)−log(ci_lower)]/[2×1.959963984540054]`. |
| P1/title, “...human disease” | The outcome panel includes biomarkers and other human traits as well as disease. The title is narrower than the resource. | Consider “A source-aware atlas of genetic correlations between sleep phenotypes and human traits.” This is a scope-accuracy suggestion, not a claim of novelty. |

Figure 2's caption should scope the HM3 fallback specifically to FinnGen while keeping MVP CI reconstruction and shared-outcome reuse explicit. Its present aggregate limitations are conservative, but precise source attribution is preferable. Do not change the frozen analysis or infer an invalid source simply from P/CI disagreement.

P4/P43's CSAIL reviewer coordination and “No participant was enrolled by this agent” in P68 are acceptable internal status notes, but should be removed/recast in a publication version. Reviewer affiliation is not scientific evidence, and project coordination is not a result. Retain accurate AI-use disclosure and accountable author declarations. This is editorial cleanup, not a reason to launch more analysis.

## Major gaps essential to this resource paper

**Demonstrate the contribution with actual scientific interpretation cases.** Results currently gives extensive reproduction/transfer counts but only two fully developed interpretation decisions. Incorporate a compact, evidence-backed use-case table showing an actual query, the frozen result and source definition, the defensible conclusion and a specific unsupported conclusion prevented. Existing material supports this without new fits: the held bowel direction, source-reused outcome validation, a QC-ineligible estimate, missing-pair abstention, and the available fitted-specification sensitivity. For example, the documented device-duration/HDL sensitivity has an interval including zero under the sensitivity specification, but no calibrated between-specification difference; that is a real interpretation boundary, not proof of differing effects. These examples should not be called empirical improvements in accuracy or trust. A designed demonstration establishes capability; the pilot is needed if the manuscript asserts measured researcher benefit.

**Obtain independent human assessment of the actual integrated results and central claim.** Ask relevant genetic-epidemiology/resource/domain reviewers whether the interpretation safeguards, benchmark scope and selected source extension establish a substantial scientific contribution. Reviewers should assess the actual estimates, held sources, figures, source assumptions and intended user decisions, not only code execution. Affiliation or five pending reviewer names cannot substitute for completed scientific assessment.

**Complete actual pilot evidence if comparative usability is intended as a principal result.** The current draft honestly contains zero responses. That is not an ethical or statistical defect in a review draft, but its benefit remains potential. An 8–12 participant feasibility pilot cannot certify broad superiority; report descriptive results, clustering/carryover limitations and incomplete tasks as frozen. Human recruitment/consent/scoring determinations remain prerequisites. If investigators instead choose a capability-only resource paper, remove empirical-benefit claims rather than fabricate responses. The user's wider objective still includes quality/usability validation, so preparation alone does not finish that objective.

**Make the claimed resource durably and permissibly available, with usable scientific methods.** A local candidate and code branch are insufficient as a completed reusable release. Accountable investigators must approve source-specific redistribution, metadata and access routes, determine institutional applicability, complete authorship/declarations, and provide durable source-linked tables and runnable instructions at the accepted release version. Cite source/preprocessing contracts sufficiently for reviewers to understand methods without private-only machine paths. An archive DOI is a desirable durable identifier; the essential requirement is an approved stable release and precise access/reproduction procedure. Partial raw replay can remain a disclosed limitation if the paper does not claim uniform end-to-end closure.

**Keep inferential uncertainties attached to the new example.** Exact MVP original CI semantics remain unverified despite the harmonized-export investigation. The result can remain conditional exploratory evidence under the current independent decision; it cannot be upgraded to schema-certified or confirmatory evidence. If investigators wish it to carry stronger biological weight, resolving that exact source contract is a genuinely useful next scientific step. An incompatible contract would require withholding inferential use. A favorable point estimate or clean arithmetic cannot settle the issue.

## What is not an essential new campaign

Fully independent two-trait replication, one molecular mechanism, genome-wide local sharing, novel covariance methods, broad tissue enrichment, and additional execution controllers are not universally mandatory for this interpretation-resource framing. They would support different/stronger claims and require compatible inputs. The present lack of admissible regional data is already disclosed, and the draft does not claim those results. Do not broaden the paper simply to fill every possible genomic-analysis category.

Likewise, remaining historical raw-provenance tails do not need to be completed before a qualified processed-input resource can be reviewed, provided source uncertainty/access and unclosed chains remain explicit. Repeated audits of unchanged inputs or repeated clean fits would not establish the missing contribution, human utility or source semantics. No genuine new mechanistic evidence has been generated by this manuscript assembly.

## Priority for the next manuscript revision

1. Apply the narrow source-attribution, inspection-scope and dependence wording corrections above.
2. Develop the existing scientific interpretation/use-case results into a focused central contribution, with compact provenance methods and reconstruction details in supplements. Keep numerical reproduction as support, not the headline advance.
3. Obtain the pending human result-focused reviews; incorporate their substantive critiques and real pilot evidence when available.
4. Finalize permitted durable resource/code access, methods and accountable declarations, retaining holds and all conditional labels.

Retain the verdict **qualified integrated scientific review draft, not submission-ready** until those essential elements are resolved. No journal acceptance guarantee is scientifically supportable.

## Inspected evidence

- Actual DOCX and builder paths above.
- V8 `source_review/statistical_scientific_actual_result_review_v8.md`; `source_admission_review_v8.md`; `qualified_native_input_contract.json`.
- V8 `reports/MVP_CI_source_closure_independent_review.md`; `SCIENTIFIC_HANDOFF_V8.md`; `integrated_release_scientific_review_v8.md`; `biological_followup_admissibility_v8.md`.
- V8 `release_candidate/sleep_constructs.tsv`, inspected for actual ascertainment/source definitions; original V4 `cell_genomics_readiness_v1/04_biological_use_cases.md`, previously inspected for existing actual examples.

V8 denotes `/Volumes/Extreme SSD/codex_sleep_gwas_atlas_v8_20261011`. Existing primary-source methodological citations and their limits are documented in the inspected independent reports. No new external literature campaign was undertaken for this manuscript review.

## Narrow correction closure

The parent applied the three material wording corrections during review. The updated builder and actual saved DOCX now bound missing MVP SE to the inspected rows, attribute the missing-INFO HapMap3 fallback to FinnGen, and identify reused GWAS summaries as the established basis for cross-estimate dependence. Those three issues are **resolved**; their earlier quoted wording above records the initial review target. No repeated numerical or scientific-source audit was performed. The explicit log-bound-difference formula remains a narrow methods-clarity recommendation, and the title/use-case table recommendations remain available. No additional unsupported biological or novelty claim was identified. The qualified review-draft verdict and substantive human/utility/release requirements are unchanged.

## Final three-recommendation closure

Inspected only the revised title, uncertainty formula wording and compact interpretation table in the updated builder and actual saved DOCX. All three recommendations are **resolved**:

- The title now specifies “human traits,” matching the broader outcome scope.
- Methods explicitly subtract the natural logarithm of the lower CI endpoint from the natural logarithm of the upper endpoint before dividing by twice 1.959963984540054. This removes the log-width ambiguity while retaining the unverified 95% log-Wald assumption.
- Actual Table 3 contains six interpretation decisions supported by the existing saved `resource_tools/scientific_query_examples.json`: complaint-insomnia/frailty retrieval; sleep-reused MVP outcome validation; bowel-direction withholding; device-duration/HDL intercept-QC exclusion; long-sleep/melanoma low-h²-precision/sensitivity limitations; and unavailable-pair abstention. The adjacent paragraph explicitly identifies these as authored demonstrations, not observed user outcomes or improved performance. The table adds a clearer demonstrated capability, not new statistical or biological results.

The narrow recommendations are closed. No fit, source reread, download, broad audit or renewed scientific review was conducted. Source-specific assumptions, actual human utility/review requirements and release clearance remain as documented; the qualified scientific-review-draft verdict is unchanged.
